Article Text
Research Article
Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease.
Abstract
A 69-year-old woman treated for 31 months with daily oral cyclophosphamide for refractory rheumatoid disease developed acute myelomonocytic leukemia 21/2 years after stopping the drug. The possibility of a casual association between the therapy and subsequent leukaemia is supported by the growing experience with cytotoxic agents.